Search research articles
Contact Us
Filters
Showing results (121-130 of 186) with videos related to
Page
of 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
H Dumez, A Awada, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer
A Hamilton, L Biganzoli, R Coleman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 10, 2000
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist
J A Kramer, D Curran, M Piccart, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 1996
Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study
E Tomiak, M Piccart, F Mignolet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H Bonnefoi, S Diebold-Berger, P Therasse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
F Efficace, L Biganzoli, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, H J Burstein, E P Winer, et al.
ESMO Open
|
September 6, 2025
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge
R Gerosa, G Gentile, L Arecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
R Paridaens, L Biganzoli, P Bruning, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A Hendlisz, V Golfinopoulos, C Garcia, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 186) with videos related to
Sort By:
Page
of 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
H Dumez, A Awada, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer
A Hamilton, L Biganzoli, R Coleman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 10, 2000
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist
J A Kramer, D Curran, M Piccart, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 1996
Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study
E Tomiak, M Piccart, F Mignolet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
H Bonnefoi, S Diebold-Berger, P Therasse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
F Efficace, L Biganzoli, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, H J Burstein, E P Winer, et al.
ESMO Open
|
September 6, 2025
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge
R Gerosa, G Gentile, L Arecco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over
R Paridaens, L Biganzoli, P Bruning, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2011
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A Hendlisz, V Golfinopoulos, C Garcia, et al.
Page
of 19